Anti T-lymphocyte globulin - Neovii Biotech

Drug Profile

Anti T-lymphocyte globulin - Neovii Biotech

Alternative Names: Anti-T-lymphocyte immune globulin; Antithymocyte globulin - Fresenius; Antithymocyte immunoglobulin (rabbit) - Neovii Biotech; ATG S Fresenius; ATG-Fresenius-S; ENZN-2053; EZ-2053; Grafalon; US-ATG-F

Latest Information Update: 22 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Fresenius Biotech
  • Developer Neovii Biotech
  • Class Polyclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Graft-versus-host disease
  • New Molecular Entity No

Highest Development Phases

  • Marketed Graft-versus-host disease; Renal transplant rejection; Transplant rejection
  • Discontinued Lung transplant rejection

Most Recent Events

  • 06 Dec 2016 Neovii Biotech completes a phase III trial for Graft-versus-host disease (Prevention) in USA and Australia
  • 03 Dec 2016 Adverse events and efficacy data from a phase III trial in Graft versus host disease presented at the 58th Annual Meeting and Exposition of the American Society of Haematology (ASH-2016)
  • 06 Oct 2016 Anti T-lymphocyte globulin (formerly antithymocyte globulin) licensed to Zydus-Cadila in India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top